New drug seems well-tolerated and merits further investigation in patients with Huntington's disease
Monday, November 7, 2011 - 18:30
in Health & Medicine
A novel drug (pridopidine) that stabilises dopamine signalling in areas of the brain that control movement and coordination, appears well tolerated and warrants further study in patients with Huntington's disease (HD), a condition characterised by an imbalance in the signalling chemical dopamine. The findings of the phase 3 MermaiHD trial are published Online First in The Lancet Neurology.